Other languages Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
7.76 ^USD	+2.51%		+19.38%	+31.97%

07:25pm	Cogent Biosciences Q1 Loss Widens	MT
02:26pm	Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cogent Biosciences Q1 Loss Widens	10:55pm
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05:56pm
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	23/02
Top Midday Gainers	15/02
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	14/02
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	10/01
Sector Update: Health Care Stocks Higher Late Afternoon	12/12
Top Midday Decliners	12/12
Sector Update: Health Care Stocks Rise Monday Afternoon	12/12
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down	11/12
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis	11/12
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis	11/12
Cogent Biosciences, Inc. Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	10/12
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
MÄRKTE USA/Uneinheitlich - Volatil nach Fed-Aussagen	15/23/15
MÄRKTE USA/Überwiegend fester - Unitedhealth brechen ein	14/23/14
MÄRKTE USA/Dow-Jones-Index von UnitedHealth belastet	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Other languages

Filters